Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, 388-1, Pungnap-2dong, Songpa-gu, Seoul 138-736, Korea.
Asan Institute for Life Sciences, University of Ulsan College of Medicine, Asan Medical Center, 388-1, Pungnap-2dong, Songpa-gu, Seoul 138-736, Korea.
Hum Reprod. 2018 May 1;33(5):807-816. doi: 10.1093/humrep/dey055.
Does interleukin-32 (IL-32) play a role in the pathogenesis of endometriosis?
IL-32 might be involved in the pathogenesis of endometriosis through increased viability, proliferation and invasion of endometrial cells.
Endometriosis is characterized as a chronic inflammatory disease and several proinflammatory cytokines are suggested to be involved in its pathogenesis and pathophysiology. IL-32, recognized as a new proinflammatory cytokine and a strong inducer of other proinflammatory cytokines, has been shown to serve as a key modulator in several chronic inflammatory diseases.
STUDY DESIGN, SIZE, DURATION: This study included comparison of IL-32 levels in the peritoneal fluids between women with and without endometriosis, in-vitro experiments using Ishikawa cells and endometrial stromal cells (ESCs), and experiments on IL-32 transgenic mice and wild-type mice with induced endometriosis.
PARTICIPANTS/MATERIALS, SETTING, METHODS: IL-32 levels in the peritoneal fluids were measured using enzyme-linked immunosorbent assays. Cell viability, expression of proliferating cell nuclear antigen (PCNA), and cellular invasiveness were analyzed following in-vitro treatment of Ishikawa cells and ESCs with recombinant IL-32 alpha (α) and gamma (γ). Ectopic endometriotic lesions were compared between IL-32 transgenic mice and wild-type mice after autologous endometrial transplantation with immunohistochemistry for Ki-67 antigen and PCNA.
The peritoneal fluid concentration of IL-32 was significantly higher in patients with advanced stage endometriosis compared with the controls. In-vitro treatment with IL-32 α and γ caused significant increases in cellular viability, PCNA expression, and invasiveness in Ishikawa cells and ESCs. The IL-32 transgenic mice had a significantly larger size of the ectopic endometrial lesions with higher expression of Ki-67 antigen and PCNA compared with wild-type mice.
N/A.
LIMITATIONS, REASONS FOR CAUTION: It is still unclear whether IL-32 is a main regulator, or one of several downstream proinflammatory cytokines, causing establishment and/or progression of endometriosis.
Further investigation on IL-32 signaling pathways may contribute to development a more effective treatment of endometriosis.
STUDY FUNDING/COMPETING INTEREST(S): This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (Grant number: HI16C1682). None of the authors has anything to disclose.
白细胞介素-32(IL-32)是否在子宫内膜异位症的发病机制中起作用?
IL-32 可能通过增加子宫内膜细胞的活力、增殖和侵袭参与子宫内膜异位症的发病机制。
子宫内膜异位症的特征是一种慢性炎症性疾病,几种促炎细胞因子被认为参与其发病机制和病理生理学。IL-32,作为一种新的促炎细胞因子和其他促炎细胞因子的强诱导剂,已被证明是几种慢性炎症性疾病中的关键调节剂。
研究设计、大小、持续时间:本研究比较了有和无子宫内膜异位症的女性腹膜液中的 IL-32 水平,使用重组 IL-32α(α)和γ(γ)对 Ishikawa 细胞和子宫内膜基质细胞(ESCs)进行体外实验,并在诱导子宫内膜异位症的 IL-32 转基因小鼠和野生型小鼠中进行实验。
参与者/材料、设置、方法:使用酶联免疫吸附试验测量腹膜液中的 IL-32 水平。用重组 IL-32α(α)和γ(γ)处理 Ishikawa 细胞和 ESCs 后,分析细胞活力、增殖细胞核抗原(PCNA)的表达和细胞侵袭性。通过免疫组织化学法检测 Ki-67 抗原和 PCNA,比较自体子宫内膜移植后 IL-32 转基因小鼠和野生型小鼠异位子宫内膜病灶的大小。
与对照组相比,晚期子宫内膜异位症患者腹膜液中 IL-32 的浓度明显升高。IL-32α和γ的体外处理导致 Ishikawa 细胞和 ESCs 的细胞活力、PCNA 表达和侵袭性显著增加。与野生型小鼠相比,IL-32 转基因小鼠的异位子宫内膜病灶明显增大,Ki-67 抗原和 PCNA 的表达水平更高。
无。
限制因素、谨慎的原因:目前尚不清楚 IL-32 是否是导致子宫内膜异位症建立和/或进展的主要调节剂,还是几种下游促炎细胞因子之一。
进一步研究 IL-32 信号通路可能有助于开发更有效的子宫内膜异位症治疗方法。
研究资金/竞争利益:本研究由韩国健康产业发展研究所(KHIDI)通过韩国卫生福利部资助的韩国卫生技术研发项目(HI16C1682)支持。作者均无任何利益冲突。